Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SPR | P35270 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985136 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRKDM4EHTT | |
| SCHEMBL984360 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRKDM4EHTT | |
| SCHEMBL7849411 | 0.82 | KDM4E (0.48) | KMT2AKDM4EALDH1A1L3MBTL1CA12 | |
| SCHEMBL9980046 | 0.80 | SPR (0.46) | HSD11B1CA12CA1CA2CA7 | |
| SCHEMBL7846882 | 0.80 | NPC1 (0.50) | MEN1KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL984997 | 0.79 | SMN1; SMN2 (0.56) | KDM4EHTTALDH1A1LMNAHSD11B1 | |
| SCHEMBL984354 | 0.79 | SMN1; SMN2 (0.56) | KDM4EHTTALDH1A1LMNAHSD11B1 | |
| SCHEMBL984356 | 0.79 | SMN1; SMN2 (0.56) | KDM4EHTTALDH1A1LMNAHSD11B1 | |
| SCHEMBL9980029 | 0.77 | CXCR2 (0.50) | — | |
| SCHEMBL9980059 | 0.77 | SPR (0.44) | KMT2AHTTALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098526-B1 | Nitrogen-containing bicyclic compounds active on chronic pain conditions | NEUROTUNE AG (CH) | 2014-01-15 | — | — | EP | claimed |
| US-20110015200-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | NEUROTUNE AG (CH) | 2011-01-20 | — | — | US | claimed |
| EP-2098526-A1 | Nitrogen-containing bicyclic compounds active on chronic pain conditions | Neurotune AG (CH) | 2009-09-09 | — | — | EP | claimed |
| WO-2009103176-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | NEUROTUNE AG (CH) | 2009-08-27 | — | — | WO | claimed |
| EP-2098526-B1 | Nitrogen-containing bicyclic compounds active on chronic pain conditions | NEUROTUNE AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| EP-2098526-B1 | Nitrogen-containing bicyclic compounds active on chronic pain conditions | NEUROTUNE AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-8334286-B2 | Substituted pyrrolo[1,2-A] pyrazines, compositions containing these, processes of making these, and uses thereof | NEUROTUNE AG (CH) | 2012-12-18 | — | — | US | disclosed |
| US-20110015200-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | NEUROTUNE AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2098526-A1 | Nitrogen-containing bicyclic compounds active on chronic pain conditions | Neurotune AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009103176-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | NEUROTUNE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015200-A1 | NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS | OPRL1, CNR1, OPRK1 | MEN1 2101/4885KMT2A 3479/4885TSHR 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.